SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study

Reuters

09/02

SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study

SeaStar Medical Holding Corporation has announced the results of a recently published health economic study concerning the QUELIMMUNE therapy, aimed at treating pediatric Acute Kidney Injury (AKI). The study, published in the Journal of Medical Economics, indicates significant cost savings, estimating a reduction of approximately 18% per hospitalization. The economic analysis projects a cost savings of $69,146 per hospitalization when QUELIMMUNE is used, compared to standard treatments. This potential cost reduction is attributed to shorter hospital stays and increased survival rates, as clinical data shows a 77% survival rate in patients treated with QUELIMMUNE. The therapy, approved by the FDA under a Humanitarian Device Exemption in 2024, is designed for pediatric patients with AKI due to sepsis or septic conditions. SeaStar Medical is also conducting the NEUTRALIZE-AKI pivotal trial to further assess the safety and efficacy of its SCD therapy in ICU patients with AKI.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521251-en) on September 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564802239"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564802239\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564802239?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564802239","market":"fut","top_or_hot":-1,"title":"SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICU\">SeaStar Medical Holding Corporation</a> has announced the results of a recently published health economic study concerning the QUELIMMUNE therapy, aimed at treating pediatric Acute Kidney Injury (AKI). The study, published in the Journal of Medical Economics, indicates significant cost savings, estimating a reduction of approximately 18% per hospitalization. The economic analysis projects a cost savings of $69,146 per hospitalization when QUELIMMUNE is used, compared to standard treatments. This potential cost reduction is attributed to shorter hospital stays and increased survival rates, as clinical data shows a 77% survival rate in patients treated with QUELIMMUNE. The therapy, approved by the FDA under a Humanitarian Device Exemption in 2024, is designed for pediatric patients with AKI due to sepsis or septic conditions. SeaStar Medical is also conducting the NEUTRALIZE-AKI pivotal trial to further assess the safety and efficacy of its SCD therapy in ICU patients with AKI.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521251-en) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-02 20:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ICU\">SeaStar Medical Holding Corporation</a> has announced the results of a recently published health economic study concerning the QUELIMMUNE therapy, aimed at treating pediatric Acute Kidney Injury (AKI). The study, published in the Journal of Medical Economics, indicates significant cost savings, estimating a reduction of approximately 18% per hospitalization. The economic analysis projects a cost savings of $69,146 per hospitalization when QUELIMMUNE is used, compared to standard treatments. This potential cost reduction is attributed to shorter hospital stays and increased survival rates, as clinical data shows a 77% survival rate in patients treated with QUELIMMUNE. The therapy, approved by the FDA under a Humanitarian Device Exemption in 2024, is designed for pediatric patients with AKI due to sepsis or septic conditions. SeaStar Medical is also conducting the NEUTRALIZE-AKI pivotal trial to further assess the safety and efficacy of its SCD therapy in ICU patients with AKI.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521251-en) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL54nXwN:1","article_id":"2564802239","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564802239","pubTimestamp":1756815736,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire  on September 02, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","ICU":"SeaStar Medical Holding Corporation","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4082":"医疗保健设备","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所"},"translate_title":"SeaStar Medical在新发表的研究中宣布使用QUELIMMUNE疗法治疗儿童AKI可显着节省成本并提高生存率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICU":0.9,"NDAQ":0.9},"content_text":"SeaStar Medical Announces Significant Cost Savings and Improved Survival Rates with QUELIMMUNE Therapy for Pediatric AKI in Newly Published Study\n    \n\nSeaStar Medical Holding Corporation has announced the results of a recently published health economic study concerning the QUELIMMUNE therapy, aimed at treating pediatric Acute Kidney Injury (AKI). The study, published in the Journal of Medical Economics, indicates significant cost savings, estimating a reduction of approximately 18% per hospitalization. The economic analysis projects a cost savings of $69,146 per hospitalization when QUELIMMUNE is used, compared to standard treatments. This potential cost reduction is attributed to shorter hospital stays and increased survival rates, as clinical data shows a 77% survival rate in patients treated with QUELIMMUNE. The therapy, approved by the FDA under a Humanitarian Device Exemption in 2024, is designed for pediatric patients with AKI due to sepsis or septic conditions. SeaStar Medical is also conducting the NEUTRALIZE-AKI pivotal trial to further assess the safety and efficacy of its SCD therapy in ICU patients with AKI.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seastar Medical Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521251-en) on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}